DUBLIN, April 7, 2022 /PRNewswire/ — ERS Genomics Limited (ERS) is pleased to announce a licensing agreement with the Central Institute for Experimental Animals (CIEA) in Japan. This is a non-exclusive license agreement granting CIEA access to the ERS CRISPR/Cas9 patent portfolio.
ERS, co-founded by Dr. Emmanuelle Charpentier, winner of the 2020 Nobel Prize for Gene Editing, provides access to core CRISPR/Cas9 intellectual property. Eighty-nine patents are held in more than eighty countries.
The CIEA is a private and independent non-profit institute, founded in 1952, with the aim of contributing to medical care and medical science based on the ethical use of animals in the modeling of diseases and treatments.
CEO, Eric Rhodes had the following statement: ‘“CRISPR/Cas9 is a powerful genome engineering tool that has revolutionized the field of biotechnology. At ERS, we are committed to making our technology accessible and available. We are pleased to be able to support CIEA, a globally recognized company world for its excellence in the development of new animal models for research.”
CIEA CEO, Ryuta Nomura had the following to say about how CRISPR/Cas9 technology benefits CIEA’s contributions to global healthcare: “Advances and Evolution of Gene Editing Technology was remarkable. CRISPR/Cas9 has actually changed not only the methodology but also the way of thinking in the field of medicine and biology.”
Financial details of the deal are not disclosed.
About ERS Genomics
ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was created to provide broad access to the foundational CRISPR/Cas9 intellectual property owned by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for the research and sale of products and services in multiple areas, including: research tools, kits, reagents; discovery of new targets for therapeutic intervention; cell lines for the discovery and screening of new drug candidates; GMP production of health products; pet and livestock health; the production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology.
For more information, please visit www.ersgenomics.com
About the Central Institute for Experimental Animals:
The Central Institute for Experimental Animals is a private and independent non-profit institute, founded in Japan in 1952 with the aim of contributing to medical care and medical science based on animal experimentation. CIEA is renowned for researching, developing, and commercializing the world’s most advanced laboratory animals and germ-free animal technologies that provide technologies such as surveillance testing, pathology testing, genetic modification, development engineering and image analysis. CIEA collaborates and cooperates with universities and research institutes in Japan and other countries, international public organizations such as the WHO, NIH, FDA, and NIBSC, and other commercial enterprises.
For more information, please visit www.ciea.or.jp/en/
Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, is the exclusive agent for ERS Genomics in Japan.
View original content for multimedia download: https://www.prnewswire.com/news-releases/crisprcas9-license-agreement-for-ers-genomics-and-ciea-301515937.html
SOURCE ERS Genomics